Ownership and insider activity for Aurora Cannabis Inc. (ACB): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Aurora Cannabis Inc. is a leading company in the global cannabis industry, focusing on the cultivation, production, and sale of various cannabis and cannabis-derived products across Canada and internationally. Beyond its core product offerings, the company engages in a broad spectrum of related activities, including the design and engineering of facilities, cannabis breeding programs, research and development, and both wholesale and retail distribution channels.
Price
| Price | $3.83 |
| Market Cap | $237M |
| Exchange | NASDAQ |
| Country | CA |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $160.3M | $90.8M | $219.6M | $161.5M | $440.3M | $300.9M | $300.9M | $179.5M | $184.3M | $112.8M |
| Short-term Investments | $15.0M | $59.6M | $143.8M | $7.0M | $3.7M | 0 | 0 | $4.0M | $550815 | $52.3M |
| Receivables | $2.3M | $15.2M | $112.8M | $53.9M | $56.2M | $41.3M | $41.3M | $45.5M | $42.2M | $44.7M |
| Inventory | $11.8M | $43.5M | $162.5M | $153.4M | $137.5M | $128.8M | $128.8M | $186.7M | $237.7M | $175.5M |
| Total Current Assets | $194.3M | $221.2M | $663.1M | $415.8M | $665.1M | $480.0M | $480.0M | $427.3M | $475.6M | $398.5M |
| Property, Plant & Equipment | $45.7M | $248.0M | $768.5M | $942.4M | $605.3M | $323.0M | $323.0M | $294.8M | $266.6M | $124.0M |
| Goodwill | $41.2M | $766.0M | $3.18B | $924.0M | $886.6M | $18.7M | $18.7M | $43.3M | $43.6M | $26.7M |
| Intangible Assets | $31.2M | $201.7M | $691.0M | $410.5M | $367.0M | $59.7M | $59.7M | $40.9M | $44.9M | $31.5M |
| Total Assets | $323.8M | $1.90B | $5.64B | $2.92B | $2.72B | $926.4M | $926.4M | $840.1M | $847.8M | $602.6M |
| Accounts Payable | $8.8M | $47.8M | $38.8M | $19.6M | $13.3M | $21.9M | $21.9M | $20.4M | $27.5M | $9.3M |
| Short-term Debt | $69244 | $2.5M | $250.6M | $152.0M | $40.9M | $147.6M | $147.6M | $57.3M | $26.7M | $5.7M |
| Total Current Liabilities | $23.5M | $75.7M | $438.0M | $271.1M | $116.2M | $237.8M | $237.8M | $124.8M | $110.2M | $67.1M |
| Long-term Debt | $63.8M | $202.1M | $396.7M | $293.7M | $292.8M | $36.2M | $36.2M | $4.9M | $40.0M | 0 |
| Total Liabilities | $104.1M | $335.9M | $1.23B | $802.6M | $686.0M | $404.6M | $404.6M | $237.2M | $242.7M | $89.5M |
| Retained Earnings | -$28.5M | $88.4M | -$287.4M | -$3.58B | -$4.32B | -$6.29B | -$6.29B | -$6.38B | -$6.33B | -$6.46B |
| Total Equity | $219.7M | $1.56B | $4.40B | $2.14B | $2.04B | $490.7M | $490.7M | $560.7M | $563.9M | $513.2M |
| Total Debt | $64.1M | $204.6M | $647.3M | $529.0M | $399.0M | $226.4M | $226.4M | $99.8M | $104.0M | $23.9M |
| Net Debt | -$111.1M | $54.2M | $283.9M | $360.5M | -$45.0M | -$74.5M | -$74.5M | -$83.8M | -$80.8M | -$141.2M |
| Working Capital | $170.7M | $145.5M | $225.1M | $144.6M | $548.8M | $242.2M | $242.2M | $302.5M | $365.4M | $331.4M |
Financial Health
| Debt / Equity | 0.04 |
| Current Ratio | 5.36 |
Profitability
| Return on Equity | -21.00% |
| Return on Invested Capital | -15.55% |
| Return on Assets | -17.83% |
| Gross Margin | 32.08% |
| Operating Margin | -29.66% |
| Net Margin | -38.15% |
Related companies: ACRS · BIOA · CGC · EDIT · HITI · IRWD · LFCR
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of ACB: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks